Genetics, diagnosis and treatment of Lynch syndrome: Old lessons and current challenges (Review)

FRANCESCA DURATURO¹, RAFFAELLA LICCARDO¹, MARINA DE ROSA¹ and PAOLA IZZO¹,²

¹Department of Molecular Medicine and Medical Biotechnology; ²CEINGE Biotecnologie Avanzate, University of Naples ‘Federico II’, Naples I-80131, Italy

Received June 21, 2018; Accepted December 20, 2018

DOI: 10.3892/ol.2019.9945

Abstract. Lynch syndrome (LS) is an autosomal dominant genetic disorder associated with germline mutations in DNA mismatch repair (MMR) genes. The carriers of pathogenic mutations in these genes have an increased risk of developing a colorectal cancer and/or LS-associated cancer. The LS-associated cancer types include carcinomas of the endometrium, small intestine, stomach, pancreas and biliary tract, ovary, brain, upper urinary tract and skin. The criteria for the clinical diagnosis of LS and the procedures of the genetic testing for identification of pathogenetic mutations carriers in MMR genes have long been known. A crucial point in the mutation detection analysis is the correct definition of the pathogenecity associated with MMR genetic variants, especially in order to include the mutation carriers in the endoscopy surveillance programs more suited to them. Therefore, this may help to improve the LS-associated cancer prevention programs. In the present review, we also report the recent discoveries in molecular genetics of LS, such as the new roles of MMR protein and immune response of MMR repair deficiency in colorectal cancer. Finally, we discuss the main therapeutic approaches, including immunotherapy, which represent a valid alternative to traditional therapeutic methods and extend the life expectancy of patients that have already developed LS-associated colorectal cancer.

Contents

1. Lynch syndrome: An overview
2. Clinical diagnosis and molecular analysis of Lynch syndrome
3. Recent discoveries in molecular genetics of Lynch syndrome
4. Management of Lynch syndrome patient with CRC
5. Conclusions

1. Lynch syndrome: An overview

Clinical features. Lynch syndrome (LS) is the most common hereditary form of colorectal cancer (CRC) with an incidence of 3-5% of all CRC, followed by Familial Adenomatous Polyposis (FAP), which accounts for less than 1% of the total CRC. LS and FAP are autosomal dominant inheritance diseases, caused by germline mutations in the DNA mismatch repair (MMR) genes and the tumor suppressor gene Adenomatous Polyposis Coli (APC), respectively (1-2). LS is also known as hereditary non-polyposis colorectal cancer (HNPCC) to highlight the absence of colon polyps and to distinguish this syndrome from FAP characterized by 100-1,000 polyps (1-4) and other hereditary syndrome of colorectal cancer, such as hamartomatous polyposis syndrome (5-7). LS patients born with a germline mutation in one of these MMR genes, and acquire inactivation of the second wild-type allele in their tumoral DNA, fulfilling Knudson's two hit hypothesis for inactivation of tumor suppressor genes. The somatic inactivation of the corresponding wild-type allele occurs almost exclusively by small mutations or (partial) gene loss, and bi-allelic inactivation then leads to complete abolition of the protein function of MMR system (3). This results in a defective DNA MMR system. LS is characterized by a high lifetime risk for tumor development, especially in the case of CRC (20-70% with average age at diagnosis 44-61), endometrial cancer (15-70% with average age at diagnosis 48-62), gastric cancer (6-13% with average age at diagnosis 56), ovarian cancer (4-12% with average age at diagnosis 42,5) and other extracolonic tumors (total risk 15%) as small intestine, brain, skin hepatobiliary and urinary tract (1). Other phenotypic features of LS subjects are preferential tumor localization in the right-sided colon, presence of multiple synchronous and metachronous colorectal cancers, poorly differentiated tumors, with a marked lymphocytic peritumoral inflammation recalling features of so-called 'Crohn's reaction' and Microsatellite instability at somatic level (8,9).

Genetic bases. LS patients present with a germline mutation in one of the MMR genes, MLH1 on chromosome 3p21,
MSH2 on chromosome 2p16, MSH6 on chromosome 2p16, PMS2 on chromosome 7p22, MLH3 on chromosome 2p16 and MSH3 on chromosome 5q11. The heteroduplex MutSa that predominantly identifies single base mism pairings is formed by MSH2 and MSH6 proteins, while MSH2 with MSH3 form the MutSβ identifying short insertions or deletions. Similar, the MutLα and MutLγ subunits are formed by MLH1-PMS2 and MLH1-MLH3, respectively, they interacts with the MutSα or MutSβ complex, stimulating excision and resynthesis of abnormal DNA (10). MSH2 and MLH1 are, thus essential for both complexes to function. Therefore, the MMR genes, MLH1 and MSH2 are defined as ‘major’ MMR genes, while the MSH6, PMS2, MLH3 and MSH3 are known as ‘minor’ MMR genes (9). Somatic inactivation of the corresponding wild-type allele occurs almost exclusively through point mutations or (partial) gene loss; bi-allelic inactivation then leads to complete abolition of the protein function. This results in a defective DNA MMR system, since MMR proteins are involved in the correction of single nucleotide mismatches and small insertions or deletions that may arise during DNA replication (11). The absence of redundant functions for MSH2 and MLH1 proteins underlies the importance of these two genes in MMR complex. Majority of mutations was found in these genes (84 and 71% respectively). Carriers of MSH2 variants show a higher incidence of extracolonic malignancy (48-61%; endometrial, gastric, ovarian and kidney cancer) than the carrier of MLH1 variants (11-42%) (12). Regard to minor genes, the MSH6 variants, until a few years ago, seemed to cause a form of ‘attenuated’ LS (13), PMS2 variants were associated with combined presence of multiple colorectal adenomas and glioblastomas (14). Recently, also mutations in MLH3 gene have been associated with brain tumors (15). MSH3 variants were associated with a classic phenotype only if they were inherited in combination with MSH2 variants (16). Recently, it was showed that biallelic mutations in MSH3 gene are causing polyposis forms similar to FAP phenotype (17). Sometimes constitutional MLH1 methylation in the LS adenomas could represent the initiation of these neoplasms and it may present as a defect that was inherited (18).

Microsatellite instability of related-LS tumors. The deficiency of MMR complex determines high rate of mutations in repetitive DNA sequences known as microsatellites. This condition is known as microsatellite instability (MSI) and is present in approximately 95% of all LS-associated cancers (18). Many genes contain repetitive sequences in their coding regions and some of these have an important role in the regulation of cell growth (19). In fact, mutations in the TGFβRII and TCF-4 genes, that normally inhibit cell growth, and in the IGF-RII and BAX genes involved in the apoptotic process (20) particularly predispose to colon cancer. Moreover, the presence of polyadenine traits in the coding sequences of the minor MMR genes, MSH6, MLH3 and MSH3, makes the same MMR genes targets of the MSI phenotype (21,22).

The sporadic CRC also display an MSI phenotype in about 15%. In this case, the MSI may be result of somatic hypermethylation of the MLH1 gene promoter. The hypermethylation at the promoter of MLH1 allele lead to silencing expression from that allele in all main somatic tissues. In 40-87% of all sporadic microsatellite unstable tumors (23) with hypermethylation of the MLH1 gene is present a specific mutation in the BRAF oncogene, usually the V600E missense mutation. This mutation is not present in LS MSI tumors in which the MSI phenotype is due to genetic alteration of MMR genes and it is not depend by epimutation (24).

Finally, another type of instability, ‘elevated microsatellite alterations at selected tetranucleotide repeats’ (EMAST), has also been identified in colon cancers. EMAST has been associated with both MSI. One known cause of EMAST is a deficiency or dysfunction of MSH3, which is required in the repair of tetranucleotide repeat mismatches in complex with MSH2. The MSH3 defect may also cause an impairment of homologous repair and increase sensitivity to some targeted therapies, such as poly (ADP-ribose) polymerase 1 (PARP1) inhibitors (25).

2. Clinical diagnosis and molecular analysis of Lynch syndrome

Clinical criteria. Identification of families affected by LS occurs by the Amsterdam Criteria (AC) and Bethesda guidelines. The clinical criteria of Amsterdam were used to identify families eligible for molecular analysis since 1990 (26). Subsequently, these criteria were modified, the AC II in order to include the other LS-related cancers (27). The Bethesda guidelines, which were less restrictive than AC, later defined (28) and take into account the MSI-status detected at tumoral tissue. The ‘Panel of Bethesda’ recommended by the National Cancer Institute include five microsatellites: two mononucleotide repeats (BAT25, BAT26) and three dinucleotide repeats (D2S123, D17S250, D5S346) (29) that are analyzed in tumoral DNA of patients with likely LS. If at least two of these repeats (40% of markers) are instability, tumoral DNA shows high instability (MSI-H), while if at least 10-30% of markers are instability, tumoral DNA shows low instability (MSI-L); when no microsatellite is instable, tumoral DNA shows stability of microsatellite sequences (MSS) (30). Subsequently, other microsatellite sequences were included in the panel test: NR21, NR22 and NR24, quasimonomorphic mononucleotide repeats in order to improve the sensitivity rate and predictive specificity of Bethesda guidelines (31,32); these three repeats (NR21, NR22 and NR24) with BAT25 and BAT26 constitute the Pentaplex Panel (31).

Molecular analysis. LS is associated with mutations in MMR genes. Most of mutations were found in the MLH1 and MSH2 genes that account for about 50 and 40% respectively of all mutations reported; about 15-20% of mutations were identified in the MSH6 and in PMS2 (33,34); few pathogenic mutations were identified in MLH3 (15) gene and so far, only one heterozygous variant in MSH3 gene was associated with LS phenotype (16). The most pathogenic variants in MMR genes are small insertions/deletions or large genetic rearrangements (large deletions/insertions) that, at protein level, result in premature stop codon formation (35,36). Moreover, several mutations identified in MMR genes are missense, silent or intronic variants. The influence of these variants on the development of cancer is often a controversial topic; therefore, they are each classified as a variant of uncertain
significance (VUS) (37). According to international recom-
mandations (Colon cancer Family Registry 2009, InSiGHT
Variant Interpretation Committee 2011) it is possible to
use a multifactorial likelihood model in an attempt to
define a pathogenic role of VUS (38). This approach is
based on the evaluation of both phenotypic and functional
features (9,39). In particular, the segregation analysis should
be considered the ‘gold standard’ for the validation of VUS
pathogenicity (34,39).

The loss of function of one MMR protein prevents to
repair’s complex to work properly and this determines a
genetic instability known as MSI at somatic level (27).

The molecular analysis to make diagnosis of LS begins
with the evaluation of the MSI status on tumoral DNA
(see above) by DNA fragment analysis using capillary
electrophoresis (38). At somatic level the MSI is detectable
by immunohistochemistry (IHC) analysis (40). Instead, the
common methods for the mutation detection analysis of
MMR genes include the use of denaturing high-performance
liquid chromatography (DHPLC) and direct sequencing for
point mutations, and multiplex ligation-dependent probe
amplification (MLPA) for large rearrangements (16,35,36).
So far, a large number of variants in Insight-group Database
(www.insightgroup.org) have been reported in MMR genes,
in particular MLH1, MSH2, MSH6 and PMS2, Table I, while
no variants in the MLH3 and MSH3 genes have been
reported. However, literature data show cases of patients with
hereditary colorectal cancer and with mutations in these two
genes (15,16).

Today, high-throughput techniques, such as next generation
sequencing, have been substituted for these methods to allow
the identification of a major number of genes involved in such
hereditary cancer forms. For example, recent findings suggested
POLE and POLD1 mutations are associated with gastrointes-
tinal malignancies, with mutations in these genes having been
identified in subjects with a Lynch-like phenotype (41).

### 3. Recent discoveries in molecular genetics of Lynch syndrome

**New roles for MMR proteins.** It is known a long time that
MMR proteins have developed various other functions in
addition to the postreplicative repair. Among these new roles
(such as prevention of reparative recombination, promotion
of meiotic crossover, expansion of repeated triplets, modulation
of microRNA biogenesis) is included the immunoglobulin
(Ig) diversification based on the ‘somatic hypermutation’
(SHM) process. This process is regulated by the MutSα
-MutLα complex, in combination with two other proteins,
AID (activation-induced cytidine deaminase) and Polβ (DNA
Polymerase ‘error-prone’) (42); in particular, MutSα deficiency
is associated with neoplastic transformation of T lympho-
cytes (43). Paradoxically, MMR maintains stability throughout
the genome but is responsible for up to 60% of the mutations
in V and S regions of the Ig locus that are important for diver-
sification antibodies (44). Therefore, a better understanding
of the intricate signaling cascades that govern antibody
diversification could help uncover the associations between
the maintenance of genomic integrity and tumorigenesis in the
adaptive immune response.

**Immune-response in LS colorectal cancer.** LS cancers
are usually referred to as MSI-H or MSI and conceptually
display a very interesting biology and clinical behavior
that is governed by the underlying mutational mechanism
of these tumors. MMR-deficient cells accumulate an abun-
dance of mutations at coding microsatellites, also found in
tumor-relevant genes. These mutations may give rise to a loss of
genction of the respective proteins but may also trigger the
translation of highly immunogenic frameshift neo-peptides
or -antigens (FSPs) (45). Such FSP antigens may be shared
if they occur in genes for which the mutational inactivation
has a growth-promoting impact that is supportive for the
development of a neoplasm. Such shared antigens may thus
occur in multiple and independently arising MMR-deficient
tumors. FSP neo-antigens are highly immunogenic due to
long mutational antigens that encompass multiple potential
epitopes (46). As these FSPs are derived from real shifts of
the reading frame of the respective gene, they usually have
a completely novel, and for the affected organism, foreign
amino acid sequence, that results from insertions or deletions
of single, individual nucleotides that alter the reading frame
of the affected genes (Fig. 1). Such frame-shift mutations
therefore generated substantially more immunogenic antigens
in comparison, for example, to single missense mutations as
they, for example, frequently occur in mutant P53 or KRAS
genes. If one considers MMR deficiency as a unique mecha-
nism of carcinogenesis, one can imagine that at the beginning
of the carcinogenic process cell clones are generated that
acquire mutations in coding microsatellites on a more random
basis. Only cells in which the mutational spectrum favours
neoplastic growth features will survive and further expand,
whereas other cells with less favourable mutational spectra
will be lost. Over time, this mechanism drives and shapes the
mutational spectrum of the surviving cell clones into a better
and better adapted status for local growth requirements.
Thus, loss of the MMR system could represent an efficient
mutational mechanism allows for a Darwinian selection
process of carcinogenesis. The extensive generation of these
neo-antigens in MSI cancers explains the pathological finding
that MSI cancers are characterized by massive infiltration of
lymphocytes and other immune-related cells that point to the
strong immunogenicity of such cancers. MSI cancer cells can
grow out to clinically manifest cancers if local T cells in their
environment become exhausted. Alternatively, MSI cancer
cells that have undergone immune evasion due to a loss of
HLA-mediated antigen presentation may grow out irrespective

### Table I. Numbers of genetic variants identified in MMR genes.

| Gene   | Accession number | Total no. of genetic variants |
|--------|------------------|-------------------------------|
| MLH1   | NM_000249.3      | 8,023                         |
| MSH2   | NM_000251.2      | 6,346                         |
| MSH6   | NM_000179.2      | 2,297                         |
| PMS2   | NM_000535.5      | 1,264                         |

All data were retrieved from the Insight Database.
of local T cell surveillance (47). Indeed, direct and indirect molecular mechanisms do not structurally interfere with the tumor cells' capacity to present FSP neoantigens, but influence the T cell activation status. In approximately 30% LS tumoral tissue mutation-induced loss of Beta 2 Microglobulin (B2M), the essential light chain of HLA class I antigens, induces a complete lack of assembled HLA class I antigens on the tumor cell surface. As a consequence, CD8-positive T cells cannot attack B2M-mutant LS cancer cells. Even mutations of the genes CIITA and RFX5, which are required for functional HLA class II antigen expression on the tumor cell surface, are found in up to 20% of MSI colorectal cancers and associated with a complete loss of HLA class II antigens on the tumor cell surface, consequently the inactivation of CD4-positive T cell (48). This may justify an endogenous immune antitumor response, counterbalanced by the expression of inhibitory immune signals, such as PD‑1 binding to the PD‑L1 receptor present on the lymphocyte membrane, inhibiting its production (Fig. 2). Immune checkpoints play a key role in limiting antitumor immunologic responses, such as those directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) receptor and its ligand, PD-L. The ligation of T-cell PD-1 by the tumor results in the downregulation of T-cell effector functions that can destroy tumor tissue. Therefore, the blockade of this pathway by anti-PD-1 antibodies prevents this downregulation, and allows T cells to maintain their antitumor functionality and ability to mediate tumor cell death (48,49).

4. Management of Lynch syndrome patient with CRC

The early detection of LS-mediated CRC progression. To improve the quality of care of patients and families with any hereditary condition resulting in gastrointestinal tumours as Lynch syndrome is the identification of carriers of relevant predisposition alleles (50). The purpose of this is reducing MMR associated hereditary colorectal cancer mortality. It is known a long time that carrier subjects of pathogenetic mutation in a MMR gene undergone to recommends annual surveillance colonoscopy from age 25 years (51). In order to include the mutation carriers in the endoscopy surveillance programs more suited to them, a crucial point is represented by correct definition of the pathogenicity of MMR genetic variants identified in the mutation detection analysis (52,53). Thus, this knowledge may helpful to improve the related-LS cancer prevention programs. Recently, MSH6 and PMS2 mutation carriers have been reported to have a lower risk of CRC with a later age of presentation (54). Indeed, literature data support
a move to commence colonoscopy surveillance in MSH6 and PMS2 mutation carriers at the older age of 30 years, providing no young index CRC, and extend the interval to 2 years (55). Therefore, the classification of MMR genetic variants is many important to choose the most appropriate endoscopic surveillance program and to precede towards a personalized medicine (56) (Fig. 3).

Therapeutic approaches of LS-related colon cancer. The choose of the optimal treatment approach for patients with metastatic colorectal cancer is based on evaluation of clinical and genomic features of tumors. It is important to take into account of the side of the colon in which the primary tumor originates, the sites and burden of metastatic disease, by mutational status of some genes, as KRAS, BRAF (57) and the MSI status on tumoral DNA (58). The most applied protocol of adjuvant chemotherapy for colorectal cancer not metastatic (stage II) involves the administration of 5-fluorouracil (5FU). Instead in some metastatic CRC cases (stage III), systemic therapy with a FOLFOX- or CAPOX (capecitabine and oxaliplatin) regimen is the standard of care in these patients. Patients with left-sided and RAS wild-type tumors receive anti-epidermal growth factor receptor (EGFR)-directed therapy, while patients with right-sided tumors or those with RAS mutations receiving bevacizumab (59). In patients with tumors that manifest microsatellite instability or deficient mismatch repair, adjuvant chemotherapy with 5-fluorouracil did not result in a survival benefit in subgroup analyses of patients with colon cancer without metastasis. While, among patients with metastatic colon cancer who received the treatment with capecitabine and oxaliplatin, survival was significantly longer among those who had deficient mismatch repair than among those who had proficient mismatch repair.

These different features are probably related to the lymphocytic infiltrate characteristic of MMR-deficient tumors that determines an antitumor immune response that may be abrogated by the immunosuppressive effects of chemotherapy (60). Despite this enhanced immunogenicity, T cells are unable to eradicate these tumors, likely due to overexpression of immune checkpoint proteins that can be antagonized by checkpoint inhibitors (Fig. 2). Recently, immune checkpoint-inhibiting agents have been developed as antitumor drugs and appear promising, especially in sporadic CRC patients with MSI. Pembrolizumab (P) is an anti-PD-1 antibody that blocks the interaction between PD-1 on T-cells, and PD-L1 and PD-L2 on tumor cells. The antibody Pembrolizumab has been evaluated in patients with metastatic colorectal cancer and MSI in whom previous treatment with cytotoxic agents had failed. The response to treatment was similar in patients with LS-related CRC and those sporadic CRC. Moreover, the combination of nivolumab, another anti-PD-1 antibody, plus ipilimumab, an anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, resulted in response rates and disease-control rates that were higher than those previously reported with nivolumab alone (61). In this context, it is interesting to note that these drugs show good results in the treatment of tumors with MSI (Fig. 3).

5. Conclusions

Identifying the mutation that causes clinical manifestations of Lynch syndrome is crucial given the relatively early onset of the disease, the high penetrance of mutations, as well as the proven efficiency of surveillance strategies. Furthermore, the studies carried out over the years on the molecular mechanisms underlying the onset of LS-related colorectal cancer have allowed us to make significant advances also in the therapeutic treatments of these tumors. Recently, immune checkpoint-inhibiting agents have been developed as antitumor drugs and appear promising, especially in sporadic CRC patients with MSI. Precisely because the subjects with Lynch syndrome show in 95% of cases MSI-H on the tumor tissue, we could say that they are ideal candidates for immunotherapeutic treatment. Finally, we hope in the near future in the context of this research will be possible to establish a preventive cancer vaccine for Lynch syndrome as recently reported by studies on the preclinical mouse model (62) (Fig. 3).
Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

Not applicable.

Authors' contributions

FD and PI designed the review. RL and MDR preformed the literature search. FD and PI interpreted the scientific articles, and FD wrote the first draft of the manuscript. FD developed the structure of the paper and the discussion. RL, MDR and PI critically revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Kohlmann W and Gruber SB: Lynch Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
2. Dodaro C, Grifasi C, Florio J, Santangelo ML, Duraturo F, De Rosa M, Izzo P and Renda A: The role of mutation analysis of the APC gene in the management of FAP patients. A controversial issue. Ann Ital Chir 87: 321-325, 2016.
3. Lynch HT, Snyder CL, Shaw TG, Heinen CD and Hitchins MP: Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer 15: 181-194, 2015.
4. De Rosa M, Galatola M, Borriello S, Duraturo F, Masone S and Izzo P: Implication of adenomatous polyposis coli and MUTYH mutations in familial colorectal polyposis. Dis Colon Rectum 52: 268-274, 2009.
5. Galatola M, Paparo L, Duraturo F, Turano M, Rossi GB, Izzo P and De Rosa M: Beta catenin and cytokine pathway dysregulation in patients with manifestations of the ‘PTEN hamartoma tumor syndrome’. BMC Med Genet 13: 28, 2012.
6. Paparo L, Rossi GB, Delrio P, Rega D, Duraturo F, Liccardo F, Debellis M, Izzo P and De Rosa M: Differential expression of PTEN gene correlates with phenotypic heterogeneity in three cases of patients showing clinical manifestations of PTEN hamartoma tumour syndrome. Hered Cancer Clin Pract 11: 8, 2013.
7. Carlomagno N, Duraturo F, Candida M, De Rosa M, Varone V, Ciancia G, Calogero A and Santangelo ML: Multiple splenic hamartomas and familial adenomatous polyposis: A case report and review of the literature. J Med Case Rep 9: 154, 2015.
8. Cudia B, Liccardo R, Di Carlo G, Damiano G, Lo Monte AI, Izzo P and Duraturo F: Clinical and anamnestic evaluation role for the diagnosis and treatment of families affected by Lynch syndrome. Case report and review of the literature. Eur J Oncol 19: 265-271, 2014.
9. Liccardo R, De Rosa M, Izzo P and Duraturo F: Novel implications in molecular diagnosis of Lynch syndrome. Gastroenterol Res Pract 2017: 2595098, 2017.
10. Peltomäki P: Deficient DNA mismatch repair: A common etiologic factor for colon cancer. Hum Mol Genet 10: 735-740, 2001.
11. Gupta R, Sinha S and Paul RN: The impact of microsatellite stability status in colorectal cancer. Curr Probl Cancer 42: 548-559, 2018.
12. Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, et al: Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol 35: 1086-1095, 2017.
13.ucci-Cordisco E, Rosella V, Carrara S, Percsepe A, Pedroni M, Bellacosa A, Calusseria O, Forasarig M, Amti M, Neril G, et al: Mutations of the ‘minor’ mismatch repair gene MSH6 in typical and atypical hereditary nonpolyposis colorectal cancer. Fam Cancer 1: 93-99, 2001.
14. Agostini M, Tibletti MG,ucci-Cordisco E, Chiaraavalli A, Morreau H, Furlan D, Boccuto L, Pucciarelli S, Capella C, Boiocchi Mand Viel A: Two PMS2 mutations in a Turcot syndrome family with small bowel cancers. Am J Gastroenterol 100: 1886-1891, 2005.
15. Duraturo F, Liccardo R and Izzo P: Coexistence of MLH3 germline variants in colon cancer patients belonging to families with Lynch syndrome-associated brain tumors. J Neurooncol 129: 577-578, 2016.
16. Duraturo F, Liccardo R, Cavallo A, De Rosa M, Grosso M and Izzo P: Association of low-risk MSH3 and MSH2 variant alleles with Lynch syndrome: Probability of synergistic effects. Int J Cancer 129: 1643-1650, 2011.
17. Adam R, Spier I, Zhao B, Kloth M, Marquez J, Hinrichsen I, Kirfel J, Taflazzoli A, Horpaopan S, Uhlhaas S, et al: Exome sequencing identifies biallelic MSH3 germline mutations as a recessive subtype of colorectal adenomatous polyposis. Am J Hum Genet 99: 337-351, 2016.
18. Boland CR: Recent discoveries in the molecular genetics of Lynch syndrome. Fam Cancer 15: 395-403, 2016.
19. Wang Y, Cheong N, Miura M and Iliakis G: Overexpression of insulin-like growth factor (IGF)-1 receptor enhances inhibition of DNA replication in mouse cells exposed to x-rays. Radiat Environ Biophys 36: 117-123, 1997.
20. Plaschke J, Krüger S, Jeske B, Theissig F, Kreuz FR, Pistorius S, Saeder HD, Iaccarino I, Marra G and Schackert HK: Loss of MSH3 protein expression is frequent in MLH1-deficient colorectal cancer and is associated with disease progression. Cancer Res 64: 864-870, 2004.
21. Loukola A, Vikki S, Singh J, Launonen V and Aaltonen LA: Germline and somatic mutation analysis of MLH3 in MSI-positive colorectal cancer. Am J Pathol 157: 347-352, 2000.
22. Alhopuro P, Sammalkorpi H, Niittymäki I, Biström M, Raitila A, Saharinen J, Nousiainen J, Lehtimäki H, Helvövaara E, Puhakkala J, et al: Candidate driver genes in microsatellite-unstable colorectal cancer. Int J Cancer 130: 1558-1566, 2012.
23. Ryan E, Sheahan K, Creavin B, Mohan HM and Winter DC: The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing. Crit Rev Oncol Hematol 116: 38-57, 2017.
24. Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA, Burgart LJ, McDowell SK, Schaid DJ and Thibodeau SN: BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 63: 5209-5212, 2003.
25. Carethers JM, Koi M and Tseng-Rogenski SS: EMAST is a form of microsatellite instability that is initiated by inflammation and modulates colorectal cancer progression. Genes (Basel) 6: 185-205, 2015.
26. Vasen HF, Mecklin JP, Watson P, Utsunomiya J, Bertario L, Lynch P, Svendsen LB, Cristofaro G, Müller H, Khan PM, et al: Surveillance in hereditary nonpolyposis colorectal cancer: An international cooperative study of 165 families. The International Collaborative Group on HNPCC. Dis Colon Rectum 36: 1-4, 1993.
27. Vasen HF, Watson P, Mecklin JP and Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116: 1453-1456, 1999.

DURATURO et al: GENETICS, DIAGNOSIS AND TREATMENT OF LYNCH SYNDROME
28. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN and Srivastava S: A National Cancer Institute Workshop on Microsatellite instability in colorectal cancer. Cancer Res 58: 5248-5257, 1998.

29. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, et al.: Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96: 261-268, 2004.

30. Villar E, Mork ME, Cuddy A, Borras E, Bannon SA, Taggart MW, Ying J, Broadus RR, Luthra R, Rodriguez-Bigas MA, et al.: Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet 207: 495-502, 2014.

31. Suraweera N, Duval A, Reperant M, Vauray C, Furlan D, Leroy K, Seruca R, Iacopetta B and Hamelin R: Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123: 1804-1811, 2002.

32. Buhard O, Suraweera N, Lectard A, Duval A and Hamelin R: Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis. Dis Markers 20: 251-257, 2004.

33. Lynch PM: The hMSSH2 and hMLH1 genes in hereditary nonpolyposis colorectal cancer. Surg Oncol Clin N Am 18: 611-624, 2009.

34. Liccardo R, De Rosa M, Rossi GB, Carluccio N, Izzo P and Duraturo F: Incomplete segregation of MSH6 frameshift variants in a kindred of Lynch syndrome. Int J Mol Sci 18: pii: E999, 2017.

35. Duraturo F, Cavallo A, Liccardo R, Cudia B, De Rosa M, Diana G and Izzo P: Contribution of large genomic rearrangements in Italian Lynch syndrome patients: Characterization of a novel intralocus deletion. Biomed Res Int 2013: 219987, 2013.

36. Liccardo R, De Rosa M, Rossi GB, Rigler G, Izzo P and Duraturo F: Characterization of novel, large duplications in the MSH2 gene of three unrelated Lynch syndrome patients. Cancer Genet 221: 19-24, 2018.

37. Rasmussen JH, Jeisen CD, Royer-Pokora B, Drost M, Tavtigian S, Hofstra RM and de Wind N: Pathological assessment of mismatch repair gene variants in Lynch syndrome: Past, present, and future. Hum Mutat 33: 1617-1625, 2012.

38. Duraturo F, Liccardo R, Cavallo A, De Rosa M, Rossi GB and Izzo P: Multivariant analysis as a method for evaluating the pathogenicity of novel genetic MLH1 variants in patients with colorectal cancer and microsatellite instability. Int J Mol Med 36: 511-517, 2015.

39. Goldgar DE, Easton DF, Byrnes GB, Spurdle AB, Iversen ES and Greenblatt MS: IARC Unclassified Genetic Variants Working Group: Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum Mutat 29: 1265-1272, 2008.

40. Kheirelseid EA, Miller N, Chang KH, Curran C, Hennessey E, Tavtigian S, Hofstra RM and de Wind N: Pathological assessment of mismatch repair gene variants in Lynch syndrome: Past, present, and future. Hum Mutat 33: 1617-1625, 2012.

41. Jansen AM, van Wezel T, van den Akker BE, Ventayol Garcia M, Ruano D, Tops CM, Wagner A, Letteboer TG, Gómez-García EB, Devilee P, et al.: Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers. Eur J Hum Genet 24: 1089-1092, 2016.

42. Zaborska J and Gearhart P: Antibody diversification caused by disrupted mismatch repair and promiscuous DNA polymerases. DNA Repair (Amst) 38: 110-116, 2016.

43. Davari K, Frankenberger S, Schmidt A, Tomi NS and Jungnickel B: Checkpoint kinase 2 is required for efficient immunoglobulin diversification. Cell Cycle 13: 3699-3699, 2014.

44. Bak ST, Sakellariou D and Pena-Diaz J: The dual nature of mismatch repair as anti-mutator and mutator: For better or for worse. Front Genet 5: 287, 2014.

45. Schuwitte Y, Linnebacher M, Ribberup E, Gebert J and von Knebel Doebertz M: Immunological peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun 4: 14, 2004.

46. Schuwitte Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, Tariverdian M, Benner A and von Knebel Doebertz M: Immune response against frameshift-induced neoepitopes in HNPPC patients and healthy HNPPC mutation carriers. Gastroenterology 134: 988-997, 2008.

47. Koi M, Tseng-Rogenski SS and Carethers JM: Inflammation-associated microsatellite alterations: Mechanisms and significance in the prognosis of patients with colorectal cancer. Gut 62: 1715-1723, 2013.

48. Bilgin B, Sendur MA, Bülent Akın M, Şener Dede D and Yalçın B: Targeting the PD-1 pathway: A new hope for gastrointestinal cancers. Curr Med Res Opin 33: 749-759, 2017.

49. Link JT and Overman MJ: Immunotherapy progress in mismatch repair-deficient colorectal cancer and future therapeutic challenges. Cancer J 18: 136-143, 2012.

50. Dominguez-Valentin M, Nakanne S, Tugeuf H, Vodak D, Ekström PO, Nissen AM, Morak M, Holinski-Feder E, Martins A, Møller P and Høvigs E: Identification of genetic variants for clinical management of familial colorectal tumors. BMC Med Genet 19: 26, 2018.

51. Giardiello FM, Allen JJ, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T, et al.: Guidelines on genetic evaluation and management of Lynch syndrome: A consensus statement by the US Multi-society task force on colorectal cancer. Am J Gastroenterol 109: 1159-1179, 2014.

52. Kanga-Parabia A, Gaff C, Flander L, Jenkins M and Keogh LA: Discussions about predictive genetic testing for Lynch syndrome: The role of health professionals and families in decisions to decline. Fam Cancer 17: 5, 2018.

53. Linnebacher B, Ladelanum S, Frederiksen BL, Smith-Hansen L and Bernstein I: Outcome of 24 years national surveillance in different hereditary colorectal cancer subgroups leading to more individualised surveillance. J Med Genet 54: 297-304, 2017.

54. Aissaoui S, Cartellier C, Seytier T, Giraud S and Calender A: Genetic mutation risk calculation in Lynch syndrome inheritance: Evaluating the utility of the PREMM2s model in Lyon: The first French study. Bull Cancer 104: 288-294, 2017.

55. Dillon JL, Gonzalez JL, DeMars L, Bloch KJ and Tafe LJ: Universal screening for Lynch syndrome in endometrial cancers: Frequency of germline mutations and identification of patients with Lynch-like syndrome. Hum Pathol 70: 121-128, 2017.

56. De Rosa M, Rega D, Costabile V, Duraturo F, Niglio A, Izzo P, Pace U and Delrio P: The biological complexity of colorectal cancer: Insights into biomarkers for early detection and personalized care. Therap Adv Gastroenterol 9: 861-886, 2016.

57. Wojas-Krzywicka K, Kalinka-Warzocha E, Reszka K, Nicos M, Szumilo J, Mańdziuk S, Szczepaniak K, Kupnicka D, Lewandowski R, Milanowski J and Krawczyk P: Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study. Adv Clin Exp Med. 7 Aug 2018 [Epub ahead of print].

58. Murcia O, Juárez M, Rodríguez-Soler M, Hernández-Illán E, Giner-Calabuig M, Alustiza M, Egovii C, Castillejo A, Alenda C, Barberá V, et al.: Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. PLoS One 13: e0203051, 2018.

59. Romero A, Peredepaya S, Shparyk Y, Bondarenko I, Mendoza Bariani G, Abdal KC, Roca E, Franke F, Melo Cruz F, Kamesh A, et al.: Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFIRI or FOLFOXIRI as first-line treatment for metastatic colorectal cancer: A multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 3: 845-855, 2018.

60. Li LS, Morales JC, Veigl M, Sedwick D, Greer S, Meyers M, Wang F, Fishel R and Boothman DA: DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. Br J Pharmacol 158: 679-692, 2009.

61. O’Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, Ejadi S, Piha-Paul SA, Steen MN, Abdul Razak AR, et al.: Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One 12: e018948, 2017.

62. von Knebel Doebertz M and Kloor M: Towards a vaccine to prevent cancer in Lynch syndrome patients. Fam Cancer 12: 307-312, 2013.